1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/21465
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSolomayer, E. F.en
dc.contributor.authorDiel, I. J.en
dc.contributor.authorSalanti, G.en
dc.contributor.authorHahn, M.en
dc.contributor.authorGollan, C.en
dc.contributor.authorSchutz, F.en
dc.contributor.authorBastert, G.en
dc.date.accessioned2015-11-24T19:15:10Z-
dc.date.available2015-11-24T19:15:10Z-
dc.identifier.issn1078-0432-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21465-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAntineoplastic Agents, Hormonal/therapeutic useen
dc.subjectBone Marrow/*pathologyen
dc.subjectBone Marrow Cells/*pathologyen
dc.subjectBreast Neoplasms/drug therapy/mortality/*pathology/surgeryen
dc.subjectChemotherapy, Adjuvanten
dc.subjectDisease-Free Survivalen
dc.subjectFemaleen
dc.subjectGoserelin/therapeutic useen
dc.subjectHumansen
dc.subjectImmunohistochemistryen
dc.subjectLymph Node Excisionen
dc.subjectLymphatic Metastasisen
dc.subjectMiddle Ageden
dc.subjectPrognosisen
dc.subjectRetrospective Studiesen
dc.subjectS Phaseen
dc.subjectSurvival Rateen
dc.subjectTamoxifen/therapeutic useen
dc.subjectTime Factorsen
dc.titleTime independence of the prognostic impact of tumor cell detection in the bone marrow of primary breast cancer patientsen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/11751508-
heal.identifier.secondaryhttp://clincancerres.aacrjournals.org/content/7/12/4102.full.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2001-
heal.abstractPURPOSE: Tumor cell detection (TCD) in bone marrow is an outstanding prognostic factor in breast cancer. There is only one other study that has investigated more than 300 patients with a median follow-up of more than 5 years (J. L. Mansi et al., Lancet, 354:197-202, 1999). We report data from 727 patients with a median follow-up period of 6.5 years. EXPERIMENTAL DESIGN: In a prospective study, intraoperatively aspirated bone marrow was screened for micrometastatic cancer cells. We used an immunocytological method (monoclonal mucin antibody 2E11; the avidin-biotin complex method). RESULTS: Forty-three percent of the patients were TCD positive. Sixty percent of the patients with distant metastases were tumor cell positive (155 of 258 patients). Forty-nine percent of the patients with positive TCD developed distant metastases (155 of 315 patients). TCD was an independent prognostic factor for clinical outcome after a median follow-up time of 6.5 years. The prognostic impact of TCD and tumor size remains constant with the time, whereas the impact of grading and progesterone receptor on risk seems to decrease with longer follow-up time. CONCLUSIONS: TCD remains an independent prognostic factor The impact of TCD does not change with longer follow-up time. TCD is a reliable prognostic factor and provides important information about the process of metastasis.en
heal.journalNameClin Cancer Resen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Solomayer-2001-Time independence of.pdf133.4 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons